PEG10 plays a crucial role in human lung cancer proliferation, progression, prognosis and metastasis

Abstract

Paternally expressed gene 10 (PEG10) has been identified as a genetic imprinted gene, which is important for apoptosis resistance in cancer cells. Mounting evidence suggests that PEG10 is expressed in the majority of hepatocellular carcinoma (HCC) cells with growth-promoting activity. In the present study, we evaluated the correlation between PEG10 expression and the clinicopathological features of lung, breast and HCC tumors, and predicted the relationship between survival and expression levels of PEG10 in lung cancer patients. Furthermore, we chose non-small cell lung cancer cell line A549 as a model to analyze the function of PEG10 in proliferation and metastasis in vitro. Our results revealed that expression of PEG10 was closely correlated with clinical TNM grade and patient prognosis in lung cancer. PEG10 enhanced cell proliferation and promoted tumor cell migration and invasion by upregulating the expression of β-catenin, MMP-2 and MMP-9, and decreased the expression of E-cadherin in the A549 cells. Our findings provide significant insight into the molecular mechanisms of lung cancer and offer novel ideas for designing new therapeutic targets for lung carcinoma.

PEG10 promotes human breast cancer cell proliferation, migration and invasion

“…Our recent report unveiled the role of PEG10 in Raji cell apoptosis resistance, proliferation, adhesion, migration and invasion (21). In addition, we demonstrated that PEG10 is associated with lung cancer progression and enhanced proliferation, carcinogenesis, migration and invasion ability of A549 cells (22). In this study, we investigated the relationship between PEG10 and breast cancer progression by bioinformatics analysis and the function of PEG10 in breast cancer cells proliferation, cell cycle, clone formation, migration and invasion by in vitro experiments.…”

“…Hence, efficient specific tumor-related genes, which could be used in the early diagnosis, prognosis and treatment of breast cancer are urgently required. PEG10 was initially identified in 2001, and since then, it has been continuously positively associated with many types of cancers, including leukemia (15,19,20), lymphoma (21), prostate cancer (12), liver cancer (13,14), and lung cancer (22). Our recent report unveiled the role of PEG10 in Raji cell apoptosis resistance, proliferation, adhesion, migration and invasion (21).…”

“…Recently, we observed that the expression of PEG10 was closely related to clinical TNM grade and patient prognosis in lung cancer through publicly available datasets. Amplifying this finding, in vitro experiments in A549 cells, indicated that PEG10 facilitated cell proliferation and promoted tumor cell migration and invasion by upregulating the expression of β-catenin, MMP-2 and MMP-9 (22). Therefore using Gene Expression Omnibus (GEO) datasets, we analyzed the relationship between PEG10 and breast cancer, and found that the high expression of PEG10 was positively correlated with the poor grade of breast cancer and closely related with overall survival of the patients.…”

TSG101 promotes the proliferation, migration and invasion of hepatocellular carcinoma cells by regulating the PEG10

“…It has been demonstrated that multiple roles have been attributed to PEG10, for example, it involves in cell proliferation, inhibition of cell apoptosis and promotion of migration and invasion . In addition, some studies have indicated that PEG10 is frequently overexpressed in multiple malignancies, such as lung cancer, hepatocellular carcinoma, B‐cell chronic lymphocytic leukemia and pancreatic cancer . The overexpression of PEG10 is significantly associated with the proliferation, migration and metastasis of such malignancies.…”

A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma

“…Regarding prediction of NF1 inactivated tumors, we observed several genes that have been linked to cancer such as QPRT, which is highly expressed in malignant pheochromocytomas as compared to benign; RSL1D1 (CSIG), which stabilizes c-myc in hepatocellular carcinoma; PPEF, which is highly expressed in astrocytic gliomas as compared to normal brain tissue [50][51][52]; and PEG10, a poor prognostic marker and regulator of proliferation, migration, and invasion in several tumor types [53][54][55]. We also observed ATF5, a gene for which expression in malignant glioma is correlated with poor survival [56].…”